This development widens the scope for CAVATAKtm, whose various forms can now can be used to attack cancer cells expressing either ICAM-1 or DAF (delay accelerating factor). I wonder what further developments in the Viralytics labs will emerge - the first we'll hear will be annoouncments of patent grants. Very encouraging news.